Drug Trial Radar · NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
768
Planned (sponsor's estimate)
Start
Mar 25, 2022
Primary completion
Dec 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 768 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Non Small Cell Lung Cancer
- c-MET
Interventions
Telisotuzumab VedotinBiological
Intravenous (IV) Infusion
DocetaxelDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)Time frame: Up to approximately 39 months
- Overall Survival (OS)Time frame: Up to approximately 39 months
Locations
317 sites in 32 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Main /ID# 247074
Birmingham, Alabama · Completed
Ironwood Cancer & Res Ctr /ID# 262446
Chandler, Arizona · Active not recruiting
Mayo Clinic Arizona /ID# 255858
Phoenix, Arizona · Active not recruiting
Onvida Health Yuma Medical Center /ID# 253625
Yuma, Arizona · Completed
City of Hope /ID# 243157
Duarte, California · Recruiting
City Of Hope - Seacliff /ID# 263143
Huntington Beach, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144
Irvine, California · Recruiting
City Of Hope - Antelope Valley /ID# 263138
Lancaster, California · Recruiting
The Oncology Institute Of Hope & Innovation -East Los A /ID# 239774
Los Angeles, California · Completed
Eisenhower Medical Center /ID# 233189
Rancho Mirage, California · Completed
Premiere Oncology Foundation /ID# 253954
Santa Monica, California · Completed
Mayo Clinic Hospital Jacksonville /ID# 254688
Jacksonville, Florida · Completed
Ocala Oncology Florida Cancer Affiliates - Main /ID# 234228
Ocala, Florida · Completed
BRCR Medical Center Inc /ID# 262344
Tamarac, Florida · Completed
Memorial University Medical Center /ID# 264081
Savannah, Georgia · Completed
Kaiser Permanente Moanalua Medical Center /ID# 238363
Honolulu, Hawaii · Recruiting
Edward-Elmhurst Cancer Center /ID# 238552
Elmhurst, Illinois · Active not recruiting
Springfield Clinic - First /ID# 262290
Springfield, Illinois · Active not recruiting
Goshen Center for Cancer Care /ID# 257734
Goshen, Indiana · Completed
Investigative Clinical Research of Indiana - Indianapolis /ID# 260468
Indianapolis, Indiana · Completed
Baptist Health Lexington /ID# 252769
Lexington, Kentucky · Completed
Dana-Farber Cancer Institute /ID# 247132
Boston, Massachusetts · Completed
Trinity Health St. Joseph Mercy Ann Arbor /ID# 232190
Ypsilanti, Michigan · Completed
Mayo Clinic Hospital Rochester /ID# 252052
Rochester, Minnesota · Active not recruiting
Hattiesburg Clinic /ID# 248033
Hattiesburg, Mississippi · Recruiting
St. Luke's Hospital - Chesterfield /ID# 251688
Chesterfield, Missouri · Completed
St. Lukes Hosp. of Kansas City /ID# 259940
Kansas City, Missouri · Recruiting
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 247567
Kansas City, Missouri · Completed
Hulston Cancer Center /ID# 232226
Springfield, Missouri · Recruiting
Saint Louis University Cancer Center /ID# 260722
St Louis, Missouri · Completed
Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 253147
Billings, Montana · Active not recruiting
Nebraska Hematology Oncology /ID# 257710
Lincoln, Nebraska · Completed
Renown Medical Group - Oncology/Hematology /ID# 247942
Reno, Nevada · Completed
Astera Cancer Care /ID# 257753
East Brunswick, New Jersey · Completed
San Juan Oncology Associates /ID# 244387
Farmington, New Mexico · Completed
Maimonides Medical Center /ID# 240783
Brooklyn, New York · Active not recruiting
Northwell Health - Monter Cancer Center /ID# 247081
Lake Success, New York · Completed
AdventHealth Hendersonville /ID# 265349
Hendersonville, North Carolina · Completed
FirstHealth of the Carolinas- Speciality Center /ID# 241279
Pinehurst, North Carolina · Completed
Genesis Cancer Care Center /ID# 239190
Zanesville, Ohio · Active not recruiting
Showing 40 of 317 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.